|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
Chiral substrates have attracted growing interest as important intermediates for catalysts, pharmaceuticals and agrochemicals and, in line with this trend, an increase in the sales volume for chiral technologies from .7 billion (2003) to billion in 2009 is forecasted by Frost & Sullivan (1). In principle, optically active compounds can be obtained by a number of different methods. In some cases, the chiral pool can provide simple and cost-effective access from natural sources.
However, the substrate spectrum is quite limited. Synthetic intermediates are often obtained as racemic mixtures. The resolution of racemates is an additional method for the synthesis of optically active molecules. On the downside, this process is often costly and time-consuming. More efficient procedures apply asymmetric catalytic systems for the synthesis of optically active intermediates. Catalysts used in these reactions can be subdivided in chemical and biological catalysts. A wide variety of chemical catalysts have been developed over the past decades. In 2001, Knowles, Noyori and Sharpless were honoured with the Nobel Prize for the development of analogous asymmetric catalysts. Nevertheless, a major drawback for these catalysts is the need of heavy metal cations as well as multi-step synthesis. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Inaugural Conference on Pre-Filled Syringes
21-22 January 2009, Crowne Plaza Hotel - St James, London, UK
SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
|
